Compare Gilead Sciences, Inc. (GILD) vs Invesco WilderHill Clean Energy ETF (PBW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Invesco WilderHill Clean Energy ETF — how do they compare? Gilead Sciences, Inc. trades at $135.5 (market cap $163.51B), while Invesco WilderHill Clean Energy ETF trades at $33.3. The key difference: Gilead Sciences, Inc. pays a 2.49% dividend while Invesco WilderHill Clean Energy ETF pays none, and Gilead Sciences, Inc. is trading nearer its 52-week high, Invesco WilderHill Clean Energy ETF nearer its low. Which is the better fit depends on your goals.
| GILD | PBW | |
|---|---|---|
Market Cap | $163.51B | — |
Sector | Health | Sector/Thematic |
52-Week High | $155.80 | $46.99 |
52-Week Low | $108.22 | $22.23 |
Enterprise Value | $178.05B | — |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
PBW trades at $33.22, down 5.03% today amid a bearish technical signal with moving averages indicating selling pressure. The ETF shows neutral momentum oscillators but faces resistance near $35. Recent news highlights clean energy sector tailwinds from energy security concerns and legislative support, though the fund remains sensitive to interest rate movements and semiconductor market volatility.
Outlook is cautious; clean energy demand offers long-term growth, but PBW's high sensitivity to Treasury yields and tech sector swings poses near-term risks. Investors should weigh sector optimism against macroeconomic headwinds and the ETF's history of volatility during rate cycles.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Invesco WilderHill Clean Energy ETF
PBW is an equal-weighted ETF that invests in U.S. companies leading the clean energy transition. It focuses on renewable energy, power conservation, and sustainable technologies like solar, wind, and energy storage.
Read more on PBW →
